Please join us on Saturday, December 2nd to hear some of the most engaging leaders in medicine speak on the rapidly evolving sphere of healthcare innovation and the ways that business and technology are poised to transform the way that healthcare is delivered in the future. The event will feature keynote speeches on exciting health innovations and interactive skills workshops. Anyone interested in healthcare management, entrepreneurship and technology is encouraged to attend.
Kathy High, MD
Dr. High, a world renowned hematologist and president of Spark Therapeutics (company leading the first FDA approved gene therapy), began her career studying the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of studies that characterized the human immune response to adeno-associated virus (AAV) vectors in a variety of target tissues.
Rod Wong, MD, MBA
Roderick T. Wong, MD is the managing partner of RTW Investments LLC, a healthcare investment firm in New York. Dr. Wong's background includes previously serving as a portfolio manager and managing director at Davidson Kempner Capital Management LLC, where he was responsible for developing the firm's healthcare investment strategy. Dr. Wong has also worked as a healthcare analyst at Sigma Capital, and as a biotechnology research associate at SG Cowen.
David Asch, MD, MBA
David Asch is executive director of the Penn Medicine Center for Innovation. He is professor of medicine, professor of anesthesiology and critical care, and professor of medical ethics and health policy at the Perelman School of Medicine, and he is professor of health care management and professor of operations and information management at the Wharton School.
Anand Shah, MD
Dr. Shah is an oncologist at the U.S. Food and Drug Administration. At the FDA, his efforts are focused on the intersection of drug development, regulatory science, big data, and health economics. As Intrapreneur-in-Residence, he is scaling the FDA Oncology Center of Excellence big data initiative, Information Exchange and Data Transformation (INFORMED), into a health technology incubator for strategic partnerships, research, and innovation.
Spark Therapeutics' mission is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. Spark Therapeutics recently announced that the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue and Gene Therapies Advisory Committee has unanimously recommended (16-0) approval of LUXTURNA™ (voretigene neparvovec), an investigational, potential one-time gene therapy, for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease (IRD).
Alan Flake, MD
Dr. Flake is an attending surgeon in the Division of Pediatric General, Thoracic and Fetal Surgery and holds the Ruth M. and Tristram C. Colket, Jr. Endowed Chair in Pediatric Surgery at The Children’s Hospital of Philadelphia. Recently, Flake led the CHOP team for developing an artificial womb, or more precisely, a Fluid-Filled Environment to Bridge Critical Time from Mother’s Womb to Outside World
Julian Harris, MD, MBA
Dr. Julian Harris is President of CareAllies, an innovative population health management services company focused on helping physician groups and delivery systems navigate the transition to value-based care. Julian joined Cigna in September 2015 to accelerate the company’s delivery of value-based products and solutions to customers and providers in local markets. He became President of CareAllies in June 2016.
Ali Behbahani, MD, MBA
Ali joined NEA in 2007 and is a Partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products.
Chris leads the HDR, Inc. health program in the eastern United States. With a career dedicated to contributing well–conceived healthcare design solutions to the community, Chris has a passion for the thoughtful creation of humane, high–performance settings to experience and deliver healthcare. An avid big picture and highly organized thinker, Chris has a particular strength and insight into the effective master planning development of integrated healthcare campuses and facility networks.
Boston Consulting Group
The Boston Consulting Group (BCG) is a global management consulting firm and the world’s leading advisor on business strategy. Now in their sixth decade, they continue not only to grow but also to embody the same timeless sense of purpose and the constant call for renewal that founder Bruce Henderson instilled at BCG's inception.
NeuroFlow is a digital health company changing the way we see brain health. CEO and co-founder, Chris Molaro, believes that “the brain is one of the greatest last frontiers of science and technology. Our minds are connected to our bodies - and in a way that we can measure." NeuroFlow's software effectively serves as a bridge, leveraging biometric data that provides direct insight into the user’s physiological and mental state.
Date and Time
Sat, December 2, 2017
10:00 AM – 6:00 PM EDT
Jordan Medical Education Center
3400 Civic Center Blvd